Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics
SUZHOU, China, June 1, 2022 /PRNewswire/ CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results and recent business highlights. Dr. Frank Jiang, CEO of CStone, commented, "As a full-fledged biopharmaceutical company, we achieved significant milestones in 2021. As of.
Luzsana to co-develop medicines with parent company Hengrui Pharma and commercialize in North America, Europe and Japan Initial pipeline focuses on 11.